Abstract
In the last few weeks, the FDA approved three new therapies for multiple myeloma: ixazomib, the first oral proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38 and SLAMF7, respectively.
Cite
CITATION STYLE
APA
Poh, A. (2016, January 1). Multiple Myeloma Gets Three New Drugs. Cancer Discovery. https://doi.org/10.1158/2159-8290.CD-NB2015-169
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free